- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- LFG316, Sham, LFG316 Lower dose
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 174
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Macular Degeneration
- Interventions
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Abilene, Texas
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- GT005
- Drug
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Human Central Nervous System Stem Cells
- Biological
- Lead sponsor
- StemCells, Inc.
- Industry
- Eligibility
- 51 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Dry Macular Degeneration
- Interventions
- Adipose Derived Stem Cells
- Biological
- Lead sponsor
- Bioheart, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Sunrise, Florida
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Interventions
- GEM103
- Drug
- Lead sponsor
- Gemini Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 26 more
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
- Interventions
- Metformin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 12
- States / cities
- Davis, California • Palo Alto, California • Sacramento, California + 7 more
- Conditions
- Geographic Atrophy
- Interventions
- FCFD4514S, sham
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years to 89 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Beverly Hills, California • San Francisco, California + 26 more
- Conditions
- Dry Age Related Macular Degeneration
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Advanced Dry AMD With Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Carl Zeiss Meditec, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab, Sham
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
- Conditions
- Geographic Atrophy
- Interventions
- Danicopan, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Active Comparator CT1812, Placebo Comparator
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more
- Conditions
- Geographic Atrophy
- Interventions
- ACU-4429, Placebo
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Age-Related Macular Degeneration
- Interventions
- OT-551, vehicle placebo
- Drug
- Lead sponsor
- Othera Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 17
- States / cities
- Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 56 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Geographic Atrophy
- Interventions
- BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Walnut Creek, California • Jacksonville, Florida • Melbourne, Florida + 6 more
- Conditions
- Age-Related Maculopathy
- Interventions
- Rheopheresis
- Device
- Lead sponsor
- OccuLogix
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 18 more
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
- Interventions
- RN6G, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Glendale, California • Inglewood, California + 5 more
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- i-Lumen AMD
- Device
- Lead sponsor
- i-Lumen Scientific AUS PTY LTD
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Manchester, Connecticut • Lemont, Illinois • Fort Worth, Texas + 1 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-2, Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Oxnard, California • Austin, Texas + 2 more
- Conditions
- Geographic Atrophy
- Interventions
- No intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Campbell, California • Glendale, California + 19 more
- Conditions
- Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
- Interventions
- Refresh Plus Preservative-free Lubricant Eye Drops
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Interventions
- CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
- Drug · Device
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Arcadia, California • Chicago, Illinois • Lexington, Kentucky + 5 more